Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD)

Q: What does CUSIP 140755307 represent in this 13F holders report?

CUSIP 140755307 is the security identifier for TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share used to aggregate holder disclosures.

Q: How many institutions held TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in Q2 2025?

48 institutional investors reported TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share for Q2 2025. Use the holders table for investor-level position and value details.

CUSIP: 140755307

Q2 2025 13F Holders as of 30 Jun 2025

Type / Class: Equity / Common Stock, par value $0.001 per share
Shares outstanding: 9,470,889
Total 13F shares: 1,922,982
Share change: +1,922,682
Total reported value: $44,387,703
Price per share: $23.33
Number of holders: 48
Value change: +$44,380,704
Number of buys: 47

Quarterly Holders Quick Answers

What is CUSIP 140755307?
CUSIP 140755307 identifies TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share in SEC institutional holdings data.

Need full ownership history?
Open the full security ownership history page.

Next holder-history checks

These links keep the next click tied to holder verification, nearby quarters, or outside-13F ownership context.

Back to full security ownership history for the broader multi-quarter picture.
Latest 13F filings for newly reported positions across managers.
Latest Schedule 13D/13G reports for ownership changes outside the 13F cadence.
SEC investors directory for manager drilldown.

Explore More Reporting Periods

Jump to adjacent filing periods for faster comparison and easier crawl discovery.

Newer quarter: Q3 2025

Recent filing periods for CUSIP 140755307:

Q1 2026 Q4 2025 Q3 2025 Q2 2025

Top shareholders of TVRD - Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (13F + 13D/G + 3/4/5)

Grouped by holder across the latest SEC ownership disclosures. Ownership % is shown only when it is directly reported or safely comparable across share classes.

Methodology: rows are grouped by holder and ranked by the holder's primary source value. — indicates unavailable or non-comparable values; "mixed-class rows" means the latest filing spans non-comparable classes.

Holder	Source	Role / Reporting	Ownership %	Shares	Holdings Value	12M Net Δ	As of	Details
Sporos Bioventures LLC	13D/G	—	9%	837,636	$19,544,812	$0	15 Apr 2025	13D/G
Slate Path Capital LP	13D/G	—	7.5%	704,118	$19,257,627	$0	30 Jun 2025	13D/G
CSL LTD	3/4/5	10%+ Owner	— class O/S missing	7,396,770	$9,024,059	—	09 Aug 2022	3/4/5
Vifor (International) Ltd	3/4/5 13D/G	10%+ Owner	2.2% from 13D/G	7,396,770	$9,024,059	—	20 Oct 2021	3/4/5 13D/G
Solas Tvardi Sidecar LLC	13D/G	—	8.1%	761,287	$4,050,047	$0	15 Apr 2025	13D/G
David J. Tweardy	13D/G	—	7%	652,398	$3,470,757	$0	15 Apr 2025	13D/G
Shaheen Wirk	3/4/5	Director	— mixed-class rows	451,194 mixed-class rows	$2,225,966	—	17 Apr 2025	3/4/5
Wallace L. Hall Jr.	3/4/5	Director	— mixed-class rows	258,756 mixed-class rows	$1,250,632	—	17 Apr 2025	3/4/5
Chalmers Derek T.	3/4/5	President & CEO, Director	— class O/S missing	991,405	$1,209,514	—	07 Sep 2021	3/4/5
VANGUARD GROUP INC	13F	Company	1.8%	168,101	$852,272	—	31 Mar 2025	13F
FARALLON CAPITAL MANAGEMENT LLC	13F	Company	1.4%	129,685	$657,503	—	31 Mar 2025	13F
RENAISSANCE TECHNOLOGIES LLC	13F	Company	0.95%	88,530	$448,847	—	31 Mar 2025	13F
BlackRock, Inc.	13F	Company	0.66%	61,869	$313,675	—	31 Mar 2025	13F
Martin Vogelbaum	3/4/5	Director	— mixed-class rows	801,007 mixed-class rows	$308,255	—	04 Jun 2024	3/4/5
TWO SIGMA ADVISERS, LP	13F	Company	0.53%	49,180	$249,343	—	31 Mar 2025	13F
GEODE CAPITAL MANAGEMENT, LLC	13F	Company	0.42%	39,366	$199,647	—	31 Mar 2025	13F
Jeffrey L. Ives	3/4/5	Director	— mixed-class rows	393,485 mixed-class rows	$148,864	—	04 Jun 2024	3/4/5
Lisa von Moltke	3/4/5	Director	— mixed-class rows	378,009 mixed-class rows	$137,257	—	04 Jun 2024	3/4/5
BANK OF AMERICA CORP /DE/	13F	Company	0.29%	27,046	$137,124	—	31 Mar 2025	13F
Helen M. Boudreau	3/4/5	Director	— mixed-class rows	345,647 mixed-class rows	$112,985	—	04 Jun 2024	3/4/5
UBS Group AG	13F	Company	0.2%	19,101	$96,842	—	31 Mar 2025	13F
Frederique Ph.D. Menzaghi	3/4/5	CHIEF SCIENTIFIC OFF,SVP-R&D	— class O/S missing	167,247	$91,986	—	01 Feb 2024	3/4/5
MILLENNIUM MANAGEMENT LLC	13F	Company	0.19%	17,420	$88,319	—	31 Mar 2025	13F
STATE STREET CORP	13F	Company	0.16%	14,889	$75,487	—	31 Mar 2025	13F
Harrison M. Bains Jr.	3/4/5	Director	— mixed-class rows	102,399 mixed-class rows	$70,074	—	01 Jun 2023	3/4/5
Christopher Posner	3/4/5	PRESIDENT AND CEO, Director	— class O/S missing	13,109	$62,268	—	28 Feb 2025	3/4/5
LPL Financial LLC	13F	Company	0.13%	12,152	$61,611	—	31 Mar 2025	13F
Thomas Charles Reilly	3/4/5	Chief Financial Officer	— mixed-class rows	77,811 mixed-class rows	$46,129	—	03 Mar 2022	3/4/5
Joana Goncalves	3/4/5	CHIEF MEDICAL OFFICER	— class O/S missing	53,365	$44,293	—	05 Apr 2024	3/4/5
Scott Terrillion	3/4/5	SEC'Y; CHIEF COMPLIANCE & G.C.	— class O/S missing	7,190	$34,224	—	28 Feb 2025	3/4/5
Richard Makara	3/4/5	VP, Head of Accting;Controller	— class O/S missing	13,583	$16,571	—	15 Jun 2022	3/4/5
Arax Advisory Partners	13F	Company	0.03%	2,606	$13,213	—	31 Mar 2025	13F
JPMORGAN CHASE & CO	13F	Company	0.02%	1,476	$7,483	—	31 Mar 2025	13F
Ryan D. Maynard	3/4/5	CHIEF FINANCIAL OFFICER	— mixed-class rows	94,500 mixed-class rows	$7,425	—	08 Feb 2024	3/4/5
MORGAN STANLEY	13F	Company	0.01%	1,114	$5,648	—	31 Mar 2025	13F
LRI Investments, LLC	13F	Company	0%	249	$1,262	—	31 Mar 2025	13F
OSAIC HOLDINGS, INC.	13F	Company	0%	133	$672	—	31 Mar 2025	13F
Allworth Financial LP	13F	Company	0%	19	$339	—	31 Mar 2025	13F
McIlrath & Eck, LLC	13F	Company	0%	61	$309	—	31 Mar 2025	13F
WELLS FARGO & COMPANY/MN	13F	Company	0%	48	$243	—	31 Mar 2025	13F
JONES FINANCIAL COMPANIES LLLP	13F	Company	0%	46	$237	—	31 Mar 2025	13F
Kiker Wealth Management, LLC	13F	Company	0%	44	$223	—	31 Mar 2025	13F
GROUP ONE TRADING LLC	13F	Company	0%	43	$218	—	31 Mar 2025	13F
HARBOUR INVESTMENTS, INC.	13F	Company	0%	42	$213	—	31 Mar 2025	13F
BNP PARIBAS FINANCIAL MARKETS	13F	Company	0%	35	$177	—	31 Mar 2025	13F
MAI Capital Management	13F	Company	0%	30	$153	—	31 Mar 2025	13F
Painted Porch Advisors LLC	13F	Company	0%	20	$101	—	31 Mar 2025	13F
CREATIVE FINANCIAL DESIGNS INC /ADV	13F	Company	0%	18	$91	—	31 Mar 2025	13F
SBI Securities Co., Ltd.	13F	Company	0%	17	$86	—	31 Mar 2025	13F
Farther Finance Advisors, LLC	13F	Company	0%	9	$44	—	31 Mar 2025	13F

Institutional Holders of Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) as of Q2 2025

As of 30 Jun 2025, Tvardi Therapeutics, Inc. - Common Stock, par value $0.001 per share (TVRD) was held by 48 institutional shareholders that filed Form 13F with the SEC. Together, they reported ownership of 1,922,982 shares. The largest 10 holders included Slate Path Capital LP, VANGUARD GROUP INC, BlackRock, Inc., 683 Capital Management, LLC, GEODE CAPITAL MANAGEMENT, LLC, FARALLON CAPITAL MANAGEMENT LLC, STATE STREET CORP, RENAISSANCE TECHNOLOGIES LLC, NORTHERN TRUST CORP, and UBS Group AG. This page lists 49 institutional shareholders reporting positions in this security for the Q2 2025 filing period.

Investor	Option	Weight %	Change %	Value $	* Price	Shares	Share Change	Activity	Report Period

Compare Q2 2025 vs Q4 2025 Across Filers

Q4 2025 holders

Q2 2025 holders

Holder diff

-16

Investor	Q4 2025 Shares	Q2 2025 Shares	Share Diff	Share Chg %	Q4 2025 Value $	Q2 2025 Value $	Value Diff $	Value Chg %

Trend: ostatnie 8 kwartałów (+ wybrane okresy porównania).

Quarterly Holders Trend

Quarterly Value Trend

Quarterly Shares Trend

* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.